These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Obinu MC; Reibaud M; Blanchard V; Moussaoui S; Imperato A Mov Disord; 2002 Jan; 17(1):13-9. PubMed ID: 11835434 [TBL] [Abstract][Full Text] [Related]
44. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. Sozio P; Cerasa LS; Laserra S; Cacciatore I; Cornacchia C; Di Filippo ES; Fulle S; Fontana A; Di Crescenzo A; Grilli M; Marchi M; Di Stefano A Eur J Pharm Sci; 2013 May; 49(2):187-98. PubMed ID: 23454012 [TBL] [Abstract][Full Text] [Related]
45. Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases. Emon MA; Kodamullil AT; Karki R; Younesi E; Hofmann-Apitius M J Alzheimers Dis; 2017; 56(2):677-686. PubMed ID: 28035920 [TBL] [Abstract][Full Text] [Related]
46. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Lamanauskas N; Nistri A Eur J Neurosci; 2008 May; 27(10):2501-14. PubMed ID: 18445055 [TBL] [Abstract][Full Text] [Related]
47. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? Bajaj S; Jain S; Vyas P; Bawa S; Vohora D Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798 [TBL] [Abstract][Full Text] [Related]
48. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Nagoshi N; Nakashima H; Fehlings MG Molecules; 2015 Apr; 20(5):7775-89. PubMed ID: 25939067 [TBL] [Abstract][Full Text] [Related]
49. [Pharmacology of Alzheimer's disease: where do we go from here?]. Sellal F; Nieoullon A; Michel G; Michel BF; Lacomblez L; Geerts H; Delini-Stula A; Bentué-Ferrer D; Bordet R; Allain H Therapie; 2005; 60(2):89-107. PubMed ID: 15969312 [TBL] [Abstract][Full Text] [Related]
50. Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease. Han M; Liu Y; Tan Q; Zhang B; Wang W; Liu J; Zhang XJ; Wang YY; Zhang JM Eur J Pharmacol; 2011 Apr; 657(1-3):104-10. PubMed ID: 21316359 [TBL] [Abstract][Full Text] [Related]
52. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674 [TBL] [Abstract][Full Text] [Related]
53. Mechanism of Neuroprotection Against Experimental Spinal Cord Injury by Riluzole or Methylprednisolone. Sámano C; Nistri A Neurochem Res; 2019 Jan; 44(1):200-213. PubMed ID: 29290040 [TBL] [Abstract][Full Text] [Related]
54. ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker. Liu Z; Zhang B; Xia S; Fang L; Gou S Eur J Med Chem; 2021 Feb; 212():112997. PubMed ID: 33189440 [TBL] [Abstract][Full Text] [Related]
55. Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. McDonnell ME; Vera MD; Blass BE; Pelletier JC; King RC; Fernandez-Metzler C; Smith GR; Wrobel J; Chen S; Wall BA; Reitz AB Bioorg Med Chem; 2012 Sep; 20(18):5642-8. PubMed ID: 22892214 [TBL] [Abstract][Full Text] [Related]
56. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Standridge JB Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008 [TBL] [Abstract][Full Text] [Related]
57. Riluzole is a promising pharmacological inhibitor of bilirubin-induced excitotoxicity in the ventral cochlear nucleus. Han GY; Li CY; Shi HB; Wang JP; Su KM; Yin XL; Yin SK CNS Neurosci Ther; 2015 Mar; 21(3):262-70. PubMed ID: 25495717 [TBL] [Abstract][Full Text] [Related]
58. Riluzole prevents soluble Aβ1-42 oligomers-induced perturbation of spontaneous discharge in the hippocampal CA1 region of rats. Ren SC; Shao H; Ji WG; Jiang HH; Xu F; Chen PZ; Mi Z; Wen B; Zhu GX; Zhu ZR Amyloid; 2015 Mar; 22(1):36-44. PubMed ID: 25472656 [TBL] [Abstract][Full Text] [Related]
59. Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool. Lazarevic V; Yang Y; Ivanova D; Fejtova A; Svenningsson P Neuropharmacology; 2018 Dec; 143():38-48. PubMed ID: 30222983 [TBL] [Abstract][Full Text] [Related]
60. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. Masse I; Bordet R; Deplanque D; Al Khedr A; Richard F; Libersa C; Pasquier F J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1624-9. PubMed ID: 16291883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]